Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab as initial therapy for previously untreated follicular lymphoma and other …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Lymphoplasmacytic Lymphoma
• Lymphoproliferative Disorder
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)

Snippet

Sponsor: Emory University | Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Status: RECRUITING